Shingles Treatment Cannabinoid Nanoplatform CBD CBG
Summary
Cannabis Bioscience International Holdings Inc published USPTO patent application US20260108537A1 on April 23, 2026 (filed October 18, 2024, Application No. 18920359), disclosing a cannabinoid-based nanoplatform for treating shingles using CBD and CBG in oral capsule and topical cream formulations with particles smaller than 200 nm. The invention targets acute shingles symptoms and postherpetic neuralgia with systemic anti-inflammatory, antiviral, and neuroprotective effects alongside localized pain and itch relief. This is a patent publication event creating no compliance obligations.
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
Cannabis Bioscience International Holdings Inc published USPTO patent application US20260108537A1 covering a cannabinoid-based nanoplatform with CBD and CBG for treating shingles via oral capsules and topical cream with sub-200nm particles targeting acute phase symptoms and postherpetic neuralgia. Filed October 18, 2024, published April 23, 2026. This is a patent publication event creating no compliance obligations. Pharmaceutical companies developing shingles or postherpetic neuralgia treatments may wish to monitor this IP activity as it matures.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Integrative Treatment for Shingles Based on Cannabinoid Compounds
Application US20260108537A1 Kind: A1 Apr 23, 2026
Assignee
Cannabis Bioscience International Holdings Inc
Inventors
Rosangel del Valle Andrades Fuentes, Nancy Paola Duarte Delgado, Nancy Rodrigues Das Fontes, Stephanie Dona Hartmann, Ana Maria Maldonado Vacca, Maria Angelica Clavijo Romero
Abstract
This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.
CPC Classifications
A61K 31/658 A61K 9/06 A61K 9/1075 A61K 9/4858 A61K 31/165 A61K 36/886 A61K 47/10 A61K 47/14 A61K 47/22 A61K 47/26 A61K 47/34 A61K 47/38
Filing Date
2024-10-18
Application No.
18920359
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.